ORIC

ORIC's stock price experienced a significant drop of 41% on April 1, 2026, following a program update for rinzimetostat (ORIC-944) that indicated its prostate cancer treatment was roughly as effective as a competitor. The company announced it would proceed with a lower 400 mg dose of rinzimetostat in a global Phase 3 trial due to tolerability concerns. Over the past year, the share price has seen an increase of 68.95% as of May 4, 2026, compared to May 5, 2025. As of May 6, 2026, ORIC's stock price was $9.28. The company reported a net loss of $35.8 million for the quarter ended March 31, 2026, with increased R&D spending. Cash, cash equivalents, and investments reached $419.7 million as of March 31, 2026, partly due to $59.9 million raised through at-the-market offerings.